Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 5101 AL 5115

Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study

Taipale H, Tanskanen A, Koponen M, Tolppanen AM, Tiihonen J, Hartikainen S.

Int Clin Psychopharmacol. 2014 Jul;29(4):216-23. doi: 10.1097/YIC.0000000000000032.

Hypertension and inflammation in Alzheimer's disease: close partners in disease development and progression!

Nelson L, Gard P, Tabet N.

J Alzheimers Dis. 2014;41(2):331-43. doi: 10.3233/JAD-140024.

The translocator protein as a drug target in Alzheimer's disease

Chua SW, Kassiou M, Ittner LM.

Expert Rev Neurother. 2014 Apr;14(4):439-48. doi: 10.1586/14737175.2014.896201.

Monoamine oxidase inhibitors: promising therapeutic agents for Alzheimer's disease (Review)

Cai Z.

Mol Med Rep. 2014 May;9(5):1533-41. doi: 10.3892/mmr.2014.2040. Epub 2014 Mar 11.

Unveiling a prescribing cascade in an older man

Rosenberg J, Rochon PA, Gill SS.

J Am Geriatr Soc. 2014 Mar;62(3):580-1. doi: 10.1111/jgs.12714.

Dementia in a dish

Doege CA, Abeliovich A.

Biol Psychiatry. 2014 Apr 1;75(7):558-64. doi: 10.1016/j.biopsych.2014.01.007. Epub 2014 Jan 27.

Network dysfunction in Alzheimer's disease and frontotemporal dementia: implications for psychiatry

Zhou J, Seeley WW.

Biol Psychiatry. 2014 Apr 1;75(7):565-73. doi: 10.1016/j.biopsych.2014.01.020. Epub 2014 Feb 4.

Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs

Talbot K.

Neurodegener Dis Manag. 2014;4(1):31-40. doi: 10.2217/nmt.13.73.

From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease?

Flaten V, Laurent C, Coelho JE, Sandau U, Batalha VL, Burnouf S, Hamdane M, Humez S, Boison D, Lopes LV, Buée L, Blum D.

Biochem Soc Trans. 2014 Apr;42(2):587-92. doi: 10.1042/BST20130229.

Atherosclerosis and Alzheimer--diseases with a common cause? Inflammation, oxysterols, vasculature

Lathe R, Sapronova A, Kotelevtsev Y.

BMC Geriatr. 2014 Mar 21;14:36. doi: 10.1186/1471-2318-14-36.

Pharmacotherapies for sleep disturbances in Alzheimer's disease

McCleery J, Cohen DA, Sharpley AL.

Cochrane Database Syst Rev. 2014 Mar 21;(3):CD009178. doi: 10.1002/14651858.CD009178.pub2.

Considering a new paradigm for Alzheimer's disease research

Langley GR.

Drug Discov Today. 2014 Aug;19(8):1114-24. doi: 10.1016/j.drudis.2014.03.013. Epub 2014 Mar 21.

Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis

Tan CC, Yu JT, Wang HF, Tan MS, Meng XF, Wang C, Jiang T, Zhu XC, Tan L.

J Alzheimers Dis. 2014;41(2):615-31. doi: 10.3233/JAD-132690.

Brain metabolite clearance: impact on Alzheimer's disease

Zolezzi JM, Inestrosa NC.

Metab Brain Dis. 2014 Sep;29(3):553-61. doi: 10.1007/s11011-014-9527-2. Epub 2014 Mar 25.

Oxidative stress in Alzheimer's disease: why did antioxidant therapy fail?

Persson T, Popescu BO, Cedazo-Minguez A.

Oxid Med Cell Longev. 2014;2014:427318. doi: 10.1155/2014/427318. Epub 2014 Jan 5.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias